ASCO22: Lung Cancer session by Jia Luo, MD
Lung cancer research targeting KRAS in non–small cell lung cancer. Dana-Farber's Jia Luo, MD discusses KRAS lung cancer treatments and exciting research in the field.
it's been over 50 years since the discovery of Wrasse family proteins. And just last year the FDA approved a first in class inhibitor targeting care as G 12 C lung cancers. And this has really been a reflection of decades of persistent iterative research from the basic to clinical continuum that has led to this moment and now we have the possibility of targeting the most common activating psychogenic lesion in cancers. So our session will cover the basics of care as lung cancers. Will also talk about the new treatments, both targeting the other care as subtypes as well as combination therapies that hopefully will thwart mechanisms of resistance. One key take home for both clinicians and investigators is to really think about baseline tissue and plasma based D. N. A. Testing at baseline and acquired resistance so that we're able to profile these individuals and enroll them on clinical trials and keep up the pace of accelerating the field. We really want to develop new and better drugs for our patients. And this is such an exciting time to be involved.
